CytomX Payables Turnover vs Price To Sales Ratio Analysis

CTMX Stock

USD 0.89 0.02 2.30%

CytomX Therapeutics financial indicator trend analysis is way more than just evaluating CytomX Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytomX Therapeutics is a good investment. Please check the relationship between CytomX Therapeutics Payables Turnover and its Price To Sales Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Payables Turnover vs Price To Sales Ratio

Payables Turnover vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytomX Therapeutics Payables Turnover account and Price To Sales Ratio. At this time, the significance of the direction appears to have almost no relationship.

The correlation between CytomX Therapeutics' Payables Turnover and Price To Sales Ratio is 0.18. Overlapping area represents the amount of variation of Payables Turnover that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of CytomX Therapeutics, assuming nothing else is changed. The correlation between historical values of CytomX Therapeutics' Payables Turnover and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Payables Turnover of CytomX Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Payables Turnover i.e., CytomX Therapeutics' Payables Turnover and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.18

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing CytomX Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CytomX Therapeutics sales, a figure that is much harder to manipulate than other CytomX Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from CytomX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.Tax Provision is likely to rise to about 3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 28.8 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	69.6M	53.2M	99.0M	53.9M
Total Revenue	69.6M	53.2M	101.2M	54.2M

Gross Profit Total Revenue

CytomX Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.88	0.88	0.7	0.65	0.9	0.6	0.56	-0.84	-0.6	0.67	0.85	0.64	-0.16	0.38	1.0	0.19	-0.11	-0.11	0.33	0.9	0.86	-0.88	0.81	0.44	0.89
Short Long Term Debt Total	0.88		0.69	0.52	0.78	0.73	0.49	0.38	-0.73	-0.44	0.87	0.73	0.56	0.0	0.41	0.87	0.15	-0.01	-0.01	0.07	0.85	0.63	-0.93	0.73	0.33	0.65
Other Current Liab	0.88	0.69		0.86	0.41	0.82	0.8	0.71	-0.77	-0.79	0.43	0.81	0.81	-0.3	0.26	0.85	0.31	-0.16	-0.16	0.65	0.73	0.75	-0.81	0.76	0.7	0.89
Total Current Liabilities	0.7	0.52	0.86		0.09	0.81	0.74	0.9	-0.52	-0.94	0.21	0.57	0.72	-0.36	0.25	0.64	0.5	-0.32	-0.32	0.84	0.69	0.59	-0.75	0.73	0.82	0.85
Total Stockholder Equity	0.65	0.78	0.41	0.09		0.36	0.15	-0.12	-0.63	0.05	0.78	0.59	0.21	0.05	0.26	0.7	-0.33	0.28	0.28	-0.29	0.61	0.32	-0.6	0.38	-0.1	0.24
Other Liab	0.9	0.73	0.82	0.81	0.36		0.55	0.69	-0.7	-0.69	0.49	0.71	0.57	-0.07	0.31	0.89	0.35	-0.22	-0.22	0.51	0.91	0.88	-0.81	0.76	0.48	0.95
Property Plant And Equipment Net	0.6	0.49	0.8	0.74	0.15	0.55		0.64	-0.49	-0.74	0.15	0.57	0.99	-0.36	0.51	0.53	0.21	-0.14	-0.14	0.62	0.4	0.52	-0.6	0.74	0.83	0.68
Current Deferred Revenue	0.56	0.38	0.71	0.9	-0.12	0.69	0.64		-0.22	-0.98	0.08	0.28	0.62	-0.26	0.18	0.5	0.49	-0.68	-0.68	0.79	0.59	0.48	-0.67	0.62	0.89	0.74
Net Debt	-0.84	-0.73	-0.77	-0.52	-0.63	-0.7	-0.49	-0.22		0.32	-0.64	-1.0	-0.53	0.32	-0.35	-0.83	-0.28	-0.38	-0.38	-0.23	-0.63	-0.8	0.63	-0.69	-0.17	-0.76
Retained Earnings	-0.6	-0.44	-0.79	-0.94	0.05	-0.69	-0.74	-0.98	0.32		-0.13	-0.38	-0.73	0.32	-0.19	-0.54	-0.5	0.57	0.57	-0.82	-0.59	-0.49	0.72	-0.64	-0.94	-0.76
Accounts Payable	0.67	0.87	0.43	0.21	0.78	0.49	0.15	0.08	-0.64	-0.13		0.61	0.24	0.24	0.18	0.69	0.05	0.12	0.12	-0.18	0.63	0.45	-0.73	0.45	0.01	0.39
Cash	0.85	0.73	0.81	0.57	0.59	0.71	0.57	0.28	-1.0	-0.38	0.61		0.61	-0.35	0.39	0.83	0.29	0.35	0.35	0.29	0.63	0.81	-0.65	0.73	0.25	0.79
Non Current Assets Total	0.64	0.56	0.81	0.72	0.21	0.57	0.99	0.62	-0.53	-0.73	0.24	0.61		-0.31	0.54	0.58	0.18	-0.13	-0.13	0.58	0.44	0.55	-0.65	0.77	0.81	0.7
Non Currrent Assets Other	-0.16	0.0	-0.3	-0.36	0.05	-0.07	-0.36	-0.26	0.32	0.32	0.24	-0.35	-0.31		-0.39	-0.11	-0.4	-0.21	-0.21	-0.35	-0.03	-0.15	0.1	-0.33	-0.36	-0.27
Other Assets	0.38	0.41	0.26	0.25	0.26	0.31	0.51	0.18	-0.35	-0.19	0.18	0.39	0.54	-0.39		0.37	-0.1	0.11	0.11	0.07	0.25	0.36	-0.31	0.74	0.25	0.35
Cash And Short Term Investments	1.0	0.87	0.85	0.64	0.7	0.89	0.53	0.5	-0.83	-0.54	0.69	0.83	0.58	-0.11	0.37		0.12	-0.11	-0.11	0.27	0.91	0.85	-0.86	0.78	0.38	0.85
Net Receivables	0.19	0.15	0.31	0.5	-0.33	0.35	0.21	0.49	-0.28	-0.5	0.05	0.29	0.18	-0.4	-0.1	0.12		-0.03	-0.03	0.42	0.2	0.36	-0.29	0.23	0.35	0.47
Good Will	-0.11	-0.01	-0.16	-0.32	0.28	-0.22	-0.14	-0.68	-0.38	0.57	0.12	0.35	-0.13	-0.21	0.11	-0.11	-0.03		1.0	-0.34	-0.24	-0.05	0.26	-0.12	-0.55	-0.18
Common Stock Total Equity	-0.11	-0.01	-0.16	-0.32	0.28	-0.22	-0.14	-0.68	-0.38	0.57	0.12	0.35	-0.13	-0.21	0.11	-0.11	-0.03	1.0		-0.34	-0.24	-0.05	0.26	-0.12	-0.55	-0.18
Common Stock Shares Outstanding	0.33	0.07	0.65	0.84	-0.29	0.51	0.62	0.79	-0.23	-0.82	-0.18	0.29	0.58	-0.35	0.07	0.27	0.42	-0.34	-0.34		0.29	0.34	-0.36	0.41	0.77	0.61
Short Term Investments	0.9	0.85	0.73	0.69	0.61	0.91	0.4	0.59	-0.63	-0.59	0.63	0.63	0.44	-0.03	0.25	0.91	0.2	-0.24	-0.24	0.29		0.71	-0.89	0.69	0.39	0.78
Non Current Liabilities Total	0.86	0.63	0.75	0.59	0.32	0.88	0.52	0.48	-0.8	-0.49	0.45	0.81	0.55	-0.15	0.36	0.85	0.36	-0.05	-0.05	0.34	0.71		-0.61	0.73	0.3	0.92
Inventory	-0.88	-0.93	-0.81	-0.75	-0.6	-0.81	-0.6	-0.67	0.63	0.72	-0.73	-0.65	-0.65	0.1	-0.31	-0.86	-0.29	0.26	0.26	-0.36	-0.89	-0.61		-0.74	-0.61	-0.75
Other Current Assets	0.81	0.73	0.76	0.73	0.38	0.76	0.74	0.62	-0.69	-0.64	0.45	0.73	0.77	-0.33	0.74	0.78	0.23	-0.12	-0.12	0.41	0.69	0.73	-0.74		0.57	0.82
Other Stockholder Equity	0.44	0.33	0.7	0.82	-0.1	0.48	0.83	0.89	-0.17	-0.94	0.01	0.25	0.81	-0.36	0.25	0.38	0.35	-0.55	-0.55	0.77	0.39	0.3	-0.61	0.57		0.58
Total Liab	0.89	0.65	0.89	0.85	0.24	0.95	0.68	0.74	-0.76	-0.76	0.39	0.79	0.7	-0.27	0.35	0.85	0.47	-0.18	-0.18	0.61	0.78	0.92	-0.75	0.82	0.58

Click cells to compare fundamentals

CytomX Therapeutics Account Relationship Matchups

CytomX Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	341.3M	358.7M	339.4M	260.9M	201.8M	284.0M
Other Current Liab	27.2M	19.9M	30.6M	24.5M	17.9M	18.0M
Total Current Liabilities	85.6M	100.9M	106.3M	152.6M	155.9M	82.7M
Total Stockholder Equity	51.1M	49.8M	89.4M	(85.8M)	(47.4M)	(45.1M)
Other Liab	179.7M	186.3M	125.7M	180.1M	207.1M	151.2M
Property Plant And Equipment Net	32.8M	29.4M	25.3M	21.0M	16.2M	14.9M
Current Deferred Revenue	51.4M	74.9M	69.3M	121.3M	132.3M	138.9M
Net Debt	(163.6M)	(167.0M)	(187.5M)	(175.6M)	(3.2M)	(3.4M)
Retained Earnings	(417.2M)	(450.1M)	(533.7M)	(722.9M)	(723.4M)	(687.3M)
Accounts Payable	4.2M	3.0M	2.8M	2.8M	1.5M	2.7M
Cash	188.4M	191.9M	205.5M	193.7M	17.2M	16.3M
Non Current Assets Total	37.9M	34.7M	29.1M	23.8M	18.9M	19.5M
Non Currrent Assets Other	2.9M	(3.4M)	(3.7M)	(3.6M)	1M	1.1M
Other Assets	2.9M	25.6M	1.8M	944K	1.1M	1.0M
Cash And Short Term Investments	296.1M	316.1M	305.2M	193.7M	174.5M	253.8M
Net Receivables	13K	798K	790K	36.0M	3.4M	5.6M
Common Stock Shares Outstanding	45.3M	46.1M	64.1M	65.7M	73.8M	48.9M
Short Term Investments	188.6M	107.7M	124.3M	99.7M	157.3M	117.8M
Liabilities And Stockholders Equity	341.3M	358.7M	339.4M	260.9M	201.8M	284.0M
Non Current Liabilities Total	204.6M	207.9M	143.7M	194.0M	93.3M	167.4M
Other Current Assets	7.2M	14.2M	4.3M	7.5M	5.0M	5.9M
Other Stockholder Equity	468.3M	500.0M	623.3M	637.1M	675.9M	709.7M
Total Liab	290.2M	308.9M	250.0M	346.6M	249.2M	250.1M
Property Plant And Equipment Gross	32.8M	29.4M	25.3M	21.0M	30.9M	16.4M
Total Current Assets	303.3M	324.0M	310.3M	237.1M	182.9M	264.6M
Accumulated Other Comprehensive Income	57K	(47K)	(242K)	10K	95K	99.8K
Short Term Debt	2.8M	3.2M	3.6M	4.1M	9.2M	5.3M
Intangible Assets	1.3M	1.2M	1.0M	875K	729K	1.1M
Property Plant Equipment	6.9M	32.8M	7.0M	6.0M	6.9M	8.3M
Net Tangible Assets	48.9M	47.7M	87.4M	(2.4M)	(2.8M)	(2.7M)
Retained Earnings Total Equity	(417.2M)	(450.1M)	(533.7M)	(623.6M)	(561.2M)	(533.1M)
Capital Surpluse	446.0M	468.3M	500.0M	623.3M	716.8M	474.2M
Non Current Liabilities Other	850K	207.9M	143.7M	262M	3.9M	3.7M
Net Invested Capital	51.1M	49.8M	89.4M	(85.8M)	(47.4M)	(45.1M)
Net Working Capital	217.7M	223.1M	204.0M	84.5M	27.0M	25.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytomX Payables Turnover vs Price To Sales Ratio Analysis

Payables Turnover vs Price To Sales Ratio

Payables Turnover vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Payables Turnover

Price To Sales Ratio

CytomX Therapeutics fundamental ratios Correlations

CytomX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytomX Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for CytomX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Common Stock Total Equity	+ 1.0	Good Will
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.95	Other Liab
Total Liab	+ 0.92	Non Current Liabilities Total
Short Term Investments	+ 0.91	Other Liab

Cash	- 1.0	Net Debt
Retained Earnings	- 0.98	Current Deferred Revenue
Other Stockholder Equity	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Total Current Liabilities
Inventory	- 0.93	Short Long Term Debt Total
Inventory	- 0.89	Short Term Investments